Back to News GenSight Biologics Announces the Results of its Combined General Meeting of May 19, 2026
Paris, France, May 20, 2026, 6:00 pm CET – GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, announced that all 28 resolutions submitted for shareholders’ vote at the Combined Shareholders’ Meeting held on May 19, 2026, and chaired by Laurence Rodriguez, Chief Executive Officer of the Company, were approved.
During the General Meeting, Ms. Rodriguez answered shareholders’ questions together with Dr. Magali Taiel, Chief Medical Officer, and Jan Eryk Umiastowski, Chief Financial Officer.
The approved resolutions notably include financial delegations that would enable the Company to continue executing its strategy.
The results of the vote by resolution and the replay of the Annual General Meeting are available on the Company’s website in the Investors section (www.gensight-biologics.com/investors-media).
